We also showed by multiplex analysis that mRNA expression levels of compiled CD80/CD86, known receptors of CTLA-4 [25], and PD-L1/PD-L2, known receptors of PD-1 [24], demonstrated improved overall survival of patients with breast cancer, including all subtypes combined and with triple negative breast cancer. Here, CD86 is linked to breast cancer.